CLM as a novel microbial ingredient elicited substantially positive anti-diabetic effects during the intake period (12 weeks), involving especially ameliorated glycemic control of FBG, peripheral insulin action, and reduced C-peptide and HbA1c, via improving insulin resistance. This evidence concerns the gene INS and Insulin resistance.